News Media Releases 2018 Invitation to the 17th Ordinary Shareholders' Meeting incl. amended agenda item 9 19.6.2018 Amended motion of the Board of Directors for agenda item 9 13.6.2018 Amendment to agenda item 9 in the invitation to the 17th Ordinary Shareholders’ Meeting on 25 June 2018 13.6.2018 Invitation to the 17th Ordinary Shareholders' Meeting 1.6.2018 Publication of Annual Report 2017/2018 and Invitation to the Ordinary Shareholders' Meeting 1.6.2018 HBM Healthcare Investments reports a profit of CHF 115.9 million for the 2017/2018 financial year; Portfolio will be enriched with further new investments; Positive outlook for the portfolio allows for a 20 percent increase of the proposed cash… 18.5.2018 Eli Lilly announces tender offer for HBM-Portfolio Company ARMO BioSciences for USD 1.6 billion 11.5.2018 HBM Healthcare Investments increases net asset value per share (NAV) by 11 percent in the 2017/2018 financial year; Net profit of around CHF 115 million expected; Share price rises by 34 percent 3.4.2018 Another successful IPO from HBM Healthcare Investments' portfolio: Homology Medicines raises USD 144 million 29.3.2018 HBM Healthcare Investments portfolio company, TandemLife, to be acquired for up to USD 250 million in cash 15.2.2018 Successful IPO of HBM-Portfolio Company ARMO BioSciences 29.1.2018 A strong third quarter further extended HBM Healthcare Investments’ profit for the first nine months of the 2017/2018 financial year to a total of CHF 85.6 million 25.1.2018 Delightful 2017 for HBM Healthcare Investments with 26% value increase of the NAV and 40% gain on the share price 3.1.2018 2017 CSL and HBM-Portfolio Company Vitaeris Announce Strategic Partnership with Option to Acquire 5.12.2017 Novartis announces tender offer for HBM-Portfolio Company Advanced Accelerator Applications for USD 3.9 billion 30.10.2017 HBM Healthcare Investment Half-Year Report September 2017 25.10.2017 Y-mAbs Therapeutics closes USD 50 million financing round led by HBM Healthcare Investments 24.10.2017 HBM Healthcare Investments announces investment of USD 30 million in Harmony Biosciences 6.10.2017 NAV Key Figures as at 30 September 2017 2.10.2017 Capital reduction completed 14.9.2017 HBM Healthcare Investments Quarterly Report June 2017 25.7.2017 NAV Key Figures as at 30 June 2017 30.6.2017 Shareholders’ Meeting approved all proposals by the Board of Directors 26.6.2017 Publication of Annual Report 2016/2017 and Invitation to the Ordinary Shareholders’ Meeting 2.6.2017 Invitation to the 16th ordinary Shareholders’ meeting 2.6.2017 Bioverativ acquires HBM-portfolio company True North Therapeutics for up to USD 825 million plus assumed cash 23.5.2017 HBM Healthcare Investments generated a profit of CHF 136.8 million for the 2016/2017 financial year and increased net asset value per share by 15.2 percent. Board of Directors proposing an increase in the cash dividend of 30 centimes, to… 16.5.2017 HBM Healthcare Investments commits EUR 20 million in growth capital to Switzerland based Amicus SA 27.4.2017 HBM Healthcare Investments expects to report a net profit of around CHF 136 million for the financial year 2016/2017 – increase of the net asset value per share of around 15 percent 3.4.2017 HBM Healthcare Investments Quarterly Report 2016 31.1.2017 Two IPOs from the HBM Healthcare Investments portfolio increase net asset value per HBM-share by CHF 2.30 27.1.2017 Net Asset Value per HBM-share of CHF 133.43 as at 31 December 2016 3.1.2017 2016 HBM Healthcare Investments Quarterly Report September 28.10.2016 HBM Healthcare Investments invests USD 10 million in True North Therapeutics 18.10.2016 Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung 4.10.2016 Rachat d’actions propres dans le but d’une réduction de capital (103 KB) 4.10.2016 HBM Healthcare Investments launches a new share buy-back programme 4.10.2016 Net asset value (NAV) of CHF 139.42 as at 30 September 2016 3.10.2016
